pooled采购如何扩大全球新型抗菌治疗药物可及性
抗菌药物耐药是现代医学重大威胁,新型抗菌药物研发因投资回报有限转向小型创新企业,这些企业常因患者少而难以盈利。本文通过定性案例研究,评估现有全球卫生 pooled采购策略扩展至新型抗菌药物的必要条件,以扩大市场可及性并保障创新者财务可行性,从而维持抗菌药物管线可持续性。
要点
- 新型抗菌药物研发转向小型创新者,其常因市场小而面临破产风险。
- pooled采购可扩大新型抗菌药物可及性并保障创新者财务可行性。
- 需评估现有全球卫生pooled采购策略扩展至新型抗菌药物的必要条件。
核心结论
- pooled采购策略扩展至新型抗菌药物可扩大患者可及性并确保创新者财务可持续性。
研究设计与样本
- 采用定性案例研究,评估现有全球卫生pooled采购策略扩展至新型抗菌药物的必要条件。
主要发现
- 小型创新者常因仅在高收入国家获批且易感感染患者少而无法售出足够产品避免破产。
- 市场可及性扩大可将新产品带给有需要的患者,同时确保创新者财务可行性。
临床怎么用
- 可考虑将pooled采购策略扩展至新型抗菌药物,以兼顾患者可及性与创新者财务可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antimicrobial resistance is among the most significant threats to modern medicine. Because of limited returns on investment, the development of novel antibacterial products has shifted toward smaller innovators. When these developers only have resources to seek regulatory approval in select high-income countries, they often cannot sell enough of their product to avoid bankruptcy because of the low number of patients with susceptible infections. A qualitative case study was conducted to assess the factors necessary for an existing global health pooled procurement strategy to expand its scope to include novel antibacterial therapeutics. Market access expansion would bring new products to patients where they are needed, while ensuring financial viability for innovators who struggle to retain financial solvency-ensuring that these critical medicines can be available for patients globally and the antimicrobial resistance pipeline can support the demand for new antibacterials for decades to come.
引用
- Swenson J. How Pooled Procurement Can Expand Access to Novel Antibacterial Therapeutics Globally. J Infect Dis. 2026. PMID: 41206081. doi:10.1093/infdis/jiaf370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。